BRAFV600E/p-ERK/p-DRP1(Ser616)促进甲状腺乳头状癌肿瘤进展与葡萄糖代谢重编程
本研究探讨BRAFV600E突变与动力相关蛋白1(DRP1)对甲状腺乳头状癌(PTC)细胞增殖、迁移、侵袭、线粒体分裂、葡萄糖代谢、活性氧生成及凋亡的影响,并评估达拉非尼与2-脱氧-D-葡萄糖(2-DG)的抑制作用。结果显示BRAFV600E/p-ERK/p-DRP1(Ser616)通路通过上调己糖激酶2增强有氧糖酵解、促进线粒体分裂降低ROS抑制凋亡,联合2-DG与达拉非尼可显著抑制BRAFV600E阳性PTC进展。
要点
- BRAFV600E突变增强PTC有氧糖酵解并抑制氧化磷酸化。
- BRAFV600E/p-ERK/p-DRP1(Ser616)通路上调己糖激酶2表达促进增殖。
- 该通路通过促进线粒体分裂、降低ROS抑制凋亡。
核心结论
- BRAFV600E/p-ERK/p-DRP1(Ser616)信号通路在葡萄糖代谢重编程中起关键作用,促进BRAFV600E阳性PTC的侵袭与进展。
- 作者认为联合使用2-DG与达拉非尼有潜力改善BRAFV600E阳性PTC患者的结局。
研究设计与样本
- 体外研究:检测BRAFV600E与DRP1对PTC细胞增殖、迁移、侵袭、线粒体分裂、葡萄糖代谢、ROS生成及凋亡的影响。
- 采用RT-qPCR评估甲状腺癌组织中关键糖酵解酶表达,Western blot与免疫组化研究BRAFV600E与DRP1的调控互作。
- 进一步在体外和体内评估DRP1在PTC中的作用及达拉非尼与2-DG的抑制效果。
主要发现
- BRAFV600E突变显著增强PTC有氧糖酵解并抑制氧化磷酸化。
- BRAFV600E/p-ERK/p-DRP1(Ser616)通路通过上调己糖激酶2表达增强细胞增殖。
- 该通路通过促进线粒体分裂和降低ROS水平抑制凋亡。
- 联合2-DG与达拉非尼显著阻碍BRAFV600E阳性PTC进展。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Papillary thyroid cancer (PTC) with the BRAFV600E mutation is associated with a poorer prognosis. BRAF inhibitors may demonstrate limited efficacy due to emerging drug resistance. The Warburg effect may have cancer therapeutic implications. It is not known if the BRAFV600E mutation is associated with altered glucose metabolism in PTC. Methods: This study examined the effect of BRAFV600E and dynamin-related protein 1 (DRP1) on various cellular processes in PTC cells, including cell proliferation, migration, invasion, mitochondrial fission, glucose metabolism, reactive oxygen species (ROS) generation, and apoptosis. We used RT-qPCR to assess the expression of key glycolytic enzymes in thyroid cancer tissues. Additionally, the regulatory interaction between BRAFV600E and DRP1 was investigated through Western blot and immunohistochemical staining. We further evaluated the impact of DRP1 in PTC and the inhibitory effects of dabrafenib and 2-deoxy-d-glucose (2-DG) in vitro and in vivo. Results: We found that the BRAFV600E mutation significantly augments aerobic glycolysis while suppressing oxidative phosphorylation in PTC. We identified the BRAFV600E/p-ERK/p-DRP1(Ser616) signaling pathway as a critical mediator in PTC progression. First, the BRAFV600E/p-ERK/p-DRP1(Ser616) signaling pathway enhances cell proliferation by upregulating hexokinase 2 expression and thereby increasing aerobic glycolysis. Second, it inhibits apoptosis by promoting mitochondrial fission and reducing ROS levels. Moreover, we demonstrated that the combination therapy of 2-DG and dabrafenib markedly impedes the progression of BRAFV600E-positive PTC. Conclusion: The BRAFV600E/p-ERK/p-DRP1(Ser616) signaling pathway plays a pivotal role in glucose metabolism reprogramming, contributing to the aggressiveness and progression of BRAFV600E-positive PTC. Our findings suggest that a combined therapeutic approach using 2-DG and dabrafenib has the potential to improve the outcome of PTC patients with BRAFV600E.
引用
- Wen SS, Wu YJ, Wang JY, et al. BRAFV600E/p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer. Thyroid. 2024. PMID: 39162997. doi:10.1089/thy.2023.0700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。